Scarica l'app Stockscreener
571.06
3.05%
16.88
Dopo l'orario di chiusura:
571.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$554.18
Aprire:
$560.44
Volume 24 ore:
946.32K
Relative Volume:
0.99
Capitalizzazione di mercato:
$62.43B
Reddito:
$14.20B
Utile/perdita netta:
$4.41B
Rapporto P/E:
14.92
EPS:
38.28
Flusso di cassa netto:
$3.54B
1 W Prestazione:
-0.30%
1M Prestazione:
-14.37%
6M Prestazione:
-43.70%
1 anno Prestazione:
-36.88%
Intervallo 1D:
$555.39
$574.72
Intervallo di 1 settimana:
$525.99
$586.03
Portata 52W:
$525.99
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
571.06 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.83 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
606.39 | 36.98B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.01 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
242.75 | 26.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Biocon Biologics Secures US Market Entry for Yesafili - Rediff MoneyWiz
Treasurer of the State of North Carolina Lowers Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Boosted by FIL Ltd - MarketBeat
Envestnet Asset Management Inc. Raises Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Distillate Capital Partners LLC Buys Shares of 32,141 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN) - Yahoo Finance
FDA Action Alert: Regeneron, Sanofi and Abeona - BioSpace
Bank of Nova Scotia Sells 8,529 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Martingale Asset Management L P Reduces Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bank of Montreal Can Has $109.18 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
APG Asset Management N.V. Purchases 59,984 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
679 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Coign Capital Advisors LLC - MarketBeat
Heritage Trust Co Purchases Shares of 2,411 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by F M Investments LLC - MarketBeat
Renaissance Technologies LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 52-Week LowHere's Why - MarketBeat
Invesco Ltd. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wells Fargo & Company MN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Legal & General Group Plc - MarketBeat
Peapack Gladstone Financial Corp Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Massachusetts Financial Services Co. MA Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amgen’s Bundling Antitrust Case Against Regeneron Proceeds - USA Herald
Cerity Partners LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amgen Can't Ditch Regeneron's Bundling Antitrust Suit - Law360
ADAR1 Capital Management LLC Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Russell Investments Group Ltd. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Citigroup Adjusts Price Target on Regeneron Pharmaceuticals to $600 From $750, Keeps Neutral Rating - MarketScreener
Next Generation Immunotherapies Market Growth Projections - openPR.com
CenterBook Partners LP Trims Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Goldman Sachs Cuts Price Target on Regeneron Pharmaceuticals to $917 From $1,019, Keeps Buy Rating - MarketScreener
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Federated Hermes Inc. - MarketBeat
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies - Benzinga
Regeneron (REGN) Price Target Cut by Guggenheim Prior to Q1 Earnings | REGN Stock News - GuruFocus
Central Retinal Vein Occlusion Therapeutics Market Size in 7MM - openPR.com
Ilmarinen Mutual Pension Insurance Co Buys 3,400 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $940 From $950, Maintains Buy Rating - MarketScreener
Prostate Cancer Pipeline Analysis and Clinical Trials - openPR.com
May 30th Options Now Available For Regeneron Pharmaceuticals - Nasdaq
Guggenheim cuts Regeneron stock price target to $940, maintains buy By Investing.com - Investing.com India
Guggenheim cuts Regeneron stock price target to $940, maintains buy - Investing.com
Biopharmaceuticals Global Overview Report 2025: Global Market to Reach $698.7 Billion by 2030, Fueled by Specialized Therapies, Such as mAb and Gene Treatments, & a Strong Pipeline - GlobeNewswire Inc.
Grantham Mayo Van Otterloo & Co. LLC Buys 10,982 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Pamalican Asset Management Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Atopic Dermatitis Pipeline 2025: Therapies Under - openPR.com
Is Regeneron Pharmaceuticals Gaining or Losing Market Support? - Benzinga
Diabetic Retinopathy Market Deep Research Report with Forecast - openPR.com
Morgan Stanley Adjusts PT on Regeneron Pharmaceuticals to $1,081 From $1,150, Keeps Overweight Rating - MarketScreener
HPV16+ Anogenital Cancers Therapeutics Market Size in 7MM - openPR.com
Orion Investment Co Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Bryce Point Capital LLC Buys New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Learn to Evaluate (REGN) using the Charts - news.stocktradersdaily.com
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):